Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by Taipei Medical University WanFang Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Taipei Medical University WanFang Hospital
ClinicalTrials.gov Identifier:
NCT01324167
First received: March 24, 2011
Last updated: March 25, 2011
Last verified: March 2011
  Purpose

The investigators would like to know the association of gene polymorphisms and metabolic adversities in clozapine-treated patients with schizophrenia in Taiwan.


Condition
Schizophrenia
Schizoaffective Disorder

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia

Resource links provided by NLM:


Further study details as provided by Taipei Medical University WanFang Hospital:

Estimated Enrollment: 80
Study Start Date: May 2010
Estimated Study Completion Date: April 2011
Detailed Description:

The atypical antipsychotics, such as olanzapine, risperidone, quetiapine, and ziprasidone, are effective in treating both the positive and negative symptoms in schizophrenia (Kelleher et al., 2002). However, atypical antipsychotics have been linked to several forms of morbidity, including obesity, hyperlipidemia, and type 2 diabetes mellitus (DM) (Bergman and Ader, 2005; Jin et al., 2004; Melkersson and Dahl, 2004). Compared with the general population, life expectancy in schizophrenic patients is shorter by as much as 20%, attributable to higher rates of suicide, accidental deaths, and natural causes such as cardiovascular disease and DM (Harris and Barraclough, 1998). Several studies have suggested that these metabolic abnormalities may lead to a greater vulnerability to cardiovascular disease and thus may contribute to the excessive mortality among schizophrenic patients.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

schizophrenia or schizoaffective disorder patients

Criteria

Inclusion Criteria:

  • fulfilled DSM-IV criteria of schizophrenia or schizoaffective disorder
  • 18-65 year of age
  • receiving clozapine for at least 6 months

Exclusion Criteria:

  • diabetes mellitus patients
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01324167

Contacts
Contact: Chun-Hsin Chen, MD 886-2-29307930 ext 53961 chunhsin57@yahoo.com.tw

Locations
Taiwan
Taipei Medical University-WanFang Hospital Recruiting
Taipei, Taiwan
Contact: Chun-Hsin Chen, MD    886-2-29307930 ext 53961    chunhsin57@yahoo.com.tw   
Sponsors and Collaborators
Taipei Medical University WanFang Hospital
Investigators
Principal Investigator: Chun-Hsin Chen, MD Taipei Medical University WanFang Hospital
  More Information

No publications provided

Responsible Party: Chun-Hsin Chen, Department of Psychiatry, WanFang Hospital
ClinicalTrials.gov Identifier: NCT01324167     History of Changes
Other Study ID Numbers: 99037
Study First Received: March 24, 2011
Last Updated: March 25, 2011
Health Authority: Taiwan: Department of Health

Keywords provided by Taipei Medical University WanFang Hospital:
schizophrenia
schizoaffective disorder

Additional relevant MeSH terms:
Psychotic Disorders
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Clozapine
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs
GABA Antagonists
GABA Agents

ClinicalTrials.gov processed this record on April 23, 2014